Amedisys Inc (AMED)

Cash ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and cash equivalents US$ in thousands 126,500 78,112 95,400 49,436 40,500 17,956 26,566 67,800 42,694 124,458 91,646 77,344 81,808 112,904 177,278 174,756 30,294 20,757 13,902 10,554
Short-term investments US$ in thousands — — — — 40 — — — — — — — — — — — — — — —
Total current liabilities US$ in thousands 473,721 468,119 462,401 353,050 355,529 367,200 427,372 380,154 374,282 454,349 449,223 456,082 456,337 437,496 442,048 316,106 326,943 314,653 313,007 297,377
Cash ratio 0.27 0.17 0.21 0.14 0.11 0.05 0.06 0.18 0.11 0.27 0.20 0.17 0.18 0.26 0.40 0.55 0.09 0.07 0.04 0.04

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($126,500K + $—K) ÷ $473,721K
= 0.27

The cash ratio of Amedisys Inc. has shown a positive trend over the past eight quarters, increasing from 0.16 in Q2 2022 to 0.36 in Q4 2023. This indicates that the company's ability to cover its current liabilities with cash and cash equivalents has improved significantly.

A cash ratio of 0.36 in Q4 2023 means that Amedisys Inc. had $0.36 in cash and cash equivalents for every dollar of current liabilities. This suggests a strong liquidity position as the company has enough liquid assets to meet its short-term obligations comfortably.

Overall, the increasing trend in the cash ratio reflects positively on Amedisys Inc.'s financial health, indicating a strengthening ability to handle its current obligations using available cash resources.